ATE496893T1 - Isochinolinonderivate und deren verwendung als medikamente - Google Patents
Isochinolinonderivate und deren verwendung als medikamenteInfo
- Publication number
- ATE496893T1 ATE496893T1 AT03814127T AT03814127T ATE496893T1 AT E496893 T1 ATE496893 T1 AT E496893T1 AT 03814127 T AT03814127 T AT 03814127T AT 03814127 T AT03814127 T AT 03814127T AT E496893 T1 ATE496893 T1 AT E496893T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- medications
- isoquinolinone derivatives
- compounds
- disclosed
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43585102P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/040275 WO2004058717A1 (en) | 2002-12-20 | 2003-12-17 | Isoquinolinone derivatives and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496893T1 true ATE496893T1 (de) | 2011-02-15 |
Family
ID=32682285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03814127T ATE496893T1 (de) | 2002-12-20 | 2003-12-17 | Isochinolinonderivate und deren verwendung als medikamente |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7265131B2 (de) |
| EP (1) | EP1572660B1 (de) |
| AT (1) | ATE496893T1 (de) |
| AU (1) | AU2003301020A1 (de) |
| DE (1) | DE60335911D1 (de) |
| ES (1) | ES2361924T3 (de) |
| TW (1) | TW200418801A (de) |
| WO (1) | WO2004058717A1 (de) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| KR20150038395A (ko) | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| US8168666B2 (en) | 2006-11-30 | 2012-05-01 | Kowa Company, Ltd. | Substituted carbinol compound |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| KR101638035B1 (ko) | 2007-01-22 | 2016-07-11 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| CL2008001903A1 (es) * | 2007-06-29 | 2009-03-06 | Harvard College | Linea celular que comprende una o mas celulas que expresan en forma estable una secuencia de acidos nucleicos que codifica un promotor regulador de esteroles y que esta unida en forma operativa a una secuencia de acidos nucleicos que codifica una etiqueta detectable; y metodo para determinar si un compuesto reduce el colesterol. |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US7919509B2 (en) | 2008-02-29 | 2011-04-05 | Kowa Company, Ltd. | 2-oxochromene derivatives |
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US7951822B2 (en) | 2008-03-31 | 2011-05-31 | Kowa Company, Ltd. | 1,3-dihydroisobenzofuran derivatives |
| US8008306B2 (en) | 2008-04-30 | 2011-08-30 | Kowa Company, Ltd. | Quinoline compounds |
| US20110237600A1 (en) * | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| WO2009144961A1 (ja) | 2008-05-29 | 2009-12-03 | 興和株式会社 | 環状リンカーを有する置換カルビノール化合物 |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| MX2011000216A (es) | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| AU2009305669A1 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| ES2542835T3 (es) * | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| EP2408300B1 (de) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CN102438991B (zh) | 2009-04-29 | 2015-08-26 | 兴和株式会社 | 具有杂环连接基的甲醇化合物 |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3238722B1 (de) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Festen formen von isochinolinonen |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| EP2734520B1 (de) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und ihre verwendung |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20141371A1 (es) | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| WO2013077921A2 (en) | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| SG11201405378VA (en) | 2012-03-02 | 2014-09-26 | Anayaderm Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN102875466A (zh) * | 2012-04-23 | 2013-01-16 | 中国药科大学 | 异喹啉酮衍生物,其制备方法及其医药用途 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| KR20160048997A (ko) | 2013-09-04 | 2016-05-04 | 알렉사르 테라퓨틱스 인코퍼레이티드 | 간 x 수용체 (lxr) 조절인자 |
| EP3041835B1 (de) | 2013-09-04 | 2020-04-08 | Ellora Therapeutics, Inc. | Modulatoren des leber-x-rezeptors (lxr) |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3964507A1 (de) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und verwendungen davon |
| AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (de) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Kombinationstherapie |
| EP3713575A4 (de) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | Polymorphe und ihre verwendung |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3830259A4 (de) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | Auf muskel abzielende komplexe und ihre verwendungen zur behandlung von fazioskapulohumeraler muskeldystrophie |
| LT3897833T (lt) | 2018-12-17 | 2026-04-27 | Vertex Pharmaceuticals Incorporated | Apol1 inhibitoriai ir jų panaudojimo būdai |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
| EP4097083A1 (de) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitoren von apol1 und verfahren zur verwendung davon |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| JP2023530271A (ja) | 2020-06-12 | 2023-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Apol1の阻害剤及びこれを使用する方法 |
| EP4178955A1 (de) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antivirale heteroarylketonderivate |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CN116693456A (zh) * | 2022-02-28 | 2023-09-05 | 复旦大学 | 异喹啉酮类化合物及其制备方法和应用 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN117486753B (zh) * | 2023-10-13 | 2026-04-03 | 天津科技大学 | 一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物、方法及在驱蚊剂中的应用 |
| CN118440034A (zh) * | 2024-04-17 | 2024-08-06 | 南京合创药业有限公司 | 一种合成3-溴呋喃的新方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452027A (en) * | 1967-07-03 | 1969-06-24 | American Home Prod | 2-hydroxyalkylisocarbostyrils |
| JPS5424882A (en) * | 1977-07-22 | 1979-02-24 | Yamanouchi Pharmaceut Co Ltd | Novel heterocyclic compounds and their preparation |
| US5115626A (en) * | 1988-09-30 | 1992-05-26 | Rapak, Inc. | Apparatus for filling flexible plastic bags carried in a continuous web and supplies therefore |
| US4969310A (en) * | 1989-05-12 | 1990-11-13 | Automated Packaging Systems, Inc. | Packaging machine and method |
| CA2028538A1 (en) * | 1989-10-27 | 1991-04-28 | Hideaki Natsugari | 4-substituted isoquinolone derivatives, their production and use |
| US5187917A (en) * | 1990-10-29 | 1993-02-23 | Cvp Systems, Inc. | Automatic packaging apparatus and method and flexible pouch therefor |
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| ATE162525T1 (de) | 1991-07-30 | 1998-02-15 | Ciba Geigy Ag | Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren |
| US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| JP3141051B2 (ja) * | 1992-10-09 | 2001-03-05 | 日清製粉株式会社 | 抗動脈硬化剤 |
| SE501545C2 (sv) * | 1993-05-05 | 1995-03-13 | Jan Jostler | Bana för förpackningsämnen samt sätt att öppna och fylla förpackningsfickor i banan |
| US5607898A (en) * | 1993-08-02 | 1997-03-04 | Idemitsu Kosan Company, Ltd. | Pyrazole derivatives |
| US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| US5642599A (en) * | 1994-11-14 | 1997-07-01 | Tisma Machinery Corporation | Automatic packaging machine for boxes with paper end liners |
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| US5747661A (en) * | 1995-01-13 | 1998-05-05 | Howard Hughes Medical Institute | Retinoid-inducible response elements |
| WO1996037493A1 (de) * | 1995-05-26 | 1996-11-28 | Bayer Aktiengesellschaft | Pyridyl-thiazole und deren verwendung zum schutz von pflanzen gegen befall durch mikroorganismen |
| EP0845460A4 (de) | 1996-05-15 | 1998-09-02 | Toray Industries | VERFAHREN ZUR HERSTELLUNG VON 4a-ARYLDECAHYDROISOCHINOLIN-DERIVATEN |
| US5939551A (en) | 1996-05-15 | 1999-08-17 | Toray Industries, Inc. | Process for producing 4a-aryldecahydroisoquinoline derivatives |
| FR2750427B1 (fr) * | 1996-06-28 | 1998-08-07 | Synthelabo | Derives de 1-oxo-1, 2-dihydroisoquinoleine-4-propanamide, leur preparation et leur application en therapeutique |
| US5743070A (en) * | 1996-08-16 | 1998-04-28 | Automated Packaging Systems, Inc. | Packaging machine, material and method |
| ZA9711537B (en) | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| EP1019059A4 (de) | 1997-01-24 | 2004-01-14 | Univ California | Verwendung von fxr, ppar-alpha- und lxr-alpha-aktivatoren zur wiederherstellung der barrierefunktion, zur förderung der epidermisdifferenzierung, und zur proliferationshemmung |
| EP0999208A4 (de) * | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | Stickstoffhaltige heterozyklische verbindungen und heilmittel zu behandlung von hyperlipämie die diese enthalten |
| FR2772760B1 (fr) * | 1997-12-22 | 2000-02-04 | Synthelabo | Derives de 3-oxazol-5-yl-1-oxo-1,2-dihydroisoquinoleine-4- propanamide, leur preparation et leur application en therapeutique |
| AU5994199A (en) | 1998-09-23 | 2000-04-10 | Alexander Mata De Urquiza | Analysis of ligand activated nuclear receptors (in vivo) |
| ES2326850T3 (es) | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| ATE274921T1 (de) | 1999-03-26 | 2004-09-15 | Hope City | Verfahren zur selektion von fxr- rezeptormodulatoren |
| JP2002543216A (ja) | 1999-04-30 | 2002-12-17 | アーチ ディベロップメント コーポレイション | ステロイド誘導体 |
| EP1190065A2 (de) | 1999-06-18 | 2002-03-27 | Cv Therapeutics, Inc. | Atp binding cassette transporter protein abc1 polypeptide |
| AU1291901A (en) | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| AU2000235960A1 (en) | 2000-02-14 | 2001-08-27 | Tularik, Inc. | Lxr modulators |
| US6673543B2 (en) | 2000-04-05 | 2004-01-06 | Tularik, Inc. | Solid phase synthesis of LXR ligands |
| AU2001262984A1 (en) | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| BR0206831A (pt) | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| DE60336901D1 (de) * | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
-
2003
- 2003-12-17 WO PCT/US2003/040275 patent/WO2004058717A1/en not_active Ceased
- 2003-12-17 AT AT03814127T patent/ATE496893T1/de not_active IP Right Cessation
- 2003-12-17 US US10/738,964 patent/US7265131B2/en not_active Expired - Lifetime
- 2003-12-17 ES ES03814127T patent/ES2361924T3/es not_active Expired - Lifetime
- 2003-12-17 DE DE60335911T patent/DE60335911D1/de not_active Expired - Lifetime
- 2003-12-17 EP EP03814127A patent/EP1572660B1/de not_active Expired - Lifetime
- 2003-12-17 AU AU2003301020A patent/AU2003301020A1/en not_active Abandoned
- 2003-12-22 TW TW092136405A patent/TW200418801A/zh unknown
-
2007
- 2007-07-27 US US11/829,324 patent/US20080132521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1572660B1 (de) | 2011-01-26 |
| AU2003301020A8 (en) | 2004-07-22 |
| WO2004058717A1 (en) | 2004-07-15 |
| TW200418801A (en) | 2004-10-01 |
| ES2361924T3 (es) | 2011-06-24 |
| US20040204447A1 (en) | 2004-10-14 |
| US20080132521A1 (en) | 2008-06-05 |
| EP1572660A1 (de) | 2005-09-14 |
| DE60335911D1 (de) | 2011-03-10 |
| AU2003301020A1 (en) | 2004-07-22 |
| WO2004058717A8 (en) | 2004-08-19 |
| US7265131B2 (en) | 2007-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60335911D1 (de) | Isochinolinonderivate und deren verwendung als medikamente | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| ATE547416T1 (de) | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel | |
| DE60221969D1 (de) | Durch piperidine-enthaltende gruppen substituierte chinoline und deren stickstoff-enthaltende derivate und ihre verwendung als antibakterielle wirkstoffe | |
| ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
| ATE555789T1 (de) | Pyridazinderivate und deren verwendung als therapeutische mittel | |
| MY137535A (en) | New pyrrolidinium derivatives | |
| DE502004006507D1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| DE60118975D1 (de) | Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation | |
| ATE311363T1 (de) | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren | |
| DE60124761D1 (de) | Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel | |
| ATE556056T1 (de) | Pyridylderivate und deren verwendung als therapeutische mittel | |
| DE69431069D1 (de) | Cyclische amidderivate als neurokinin a antagonisten | |
| DE60305484D1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| DE60325493D1 (de) | Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten | |
| DE602004012758D1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
| ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| DE602004031410D1 (de) | Inden derivate als pharmazeutika | |
| DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0300105D0 (sv) | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof | |
| DE69803383D1 (de) | Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |